Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Urine test could spot bladder cancer without a scope

NCT ID NCT04943380

Diagnosis Sponsor: Pacific Edge Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether a urine test called Cxbladder can accurately detect bladder cancer in 682 people who had blood in their urine. The test's results were compared to the standard method, a camera exam of the bladder (cystoscopy). The goal was to see if the urine test could reliably identify who has cancer and who does not, potentially reducing the need for invasive procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

682 people

The number who actually took part.

Started

Nov 2019

Finished

Jan 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will be conducted with all hematuria patients who present to an outpatient clinic to undergo clinical assessment including cystoscopy and who fulfil study requirements. Consented eligible patients will attend their scheduled clinic visit and undergo all standard tests as clinically indicated.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient is undergoing investigation of recent confirmed hematuria (by either flexible or rigid cystoscopy/TURBT), including hematuria patients referred due to suspicious/positive imaging, in order to determine the presence of urothelial carcinoma. * Able to provide a voided urine sample of the required minimum volume * Able to give written consent * Able and willing to comply with study requirements * Aged 18 years or older Exclusion Criteria: * Prior history of bladder malignancy, prostate or renal cell carcinoma * Prior genitourinary manipulation (flexible or rigid cystoscopy / catheterisation, urethral dilation) in the 14 days before urine collection * Previous alkylating based chemotherapy * Known Pregnancy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematuria are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hematuria transitional cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematuria Urothelial carcinoma

Contacts and locations

Locations

  • Bay Pines Veterans Affairs

    Bay Pines, Florida, 33744-8200, United States

  • James A Haley Veterans' Hospital

    Tampa, Florida, 33612-4745, United States

  • James J. Peters VAMC

    New York, New York, 10468-3904, United States

  • Medical University of South Carolina

    Charleston, South Carolina, 29401, United States

  • Minneapolis VA Health Care System

    Minneapolis, Minnesota, 55417, United States

  • NWIHCS-Omaha VA Medical Center

    Omaha, Nebraska, 68105, United States

  • Oklahoma City VA Hospital

    Oklahoma City, Oklahoma, 73104, United States

  • South Florida Veterans Affairs

    Miami, Florida, 33125, United States

  • Veterans Medical Research Foundation

    San Diego, California, 92161, United States

  • White River Junction VAMC

    White River Junction, Vermont, 05009, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.